NPPB and hydrops fetalis: Finally, the EMPULSE trial demonstrated that early inpatient initiation of empagliflozin reduced the hierarchical composite outcome of all-cause mortality, HF events, or symptoms at 90 days versus placebo [50], while also improving diuretic efficiency and causing larger reductions in NT-proBNP within 30 days.